Systematic Review of Cerebroside Carnosine for Acute Ischemic Stroke

Zhang Yuqiu,Li Huiqiang,Zhai Suodi

DOI: https://doi.org/10.19960/j.cnki.issn1005-0698.2009.04.010

2009-01-01

Abstract:Objective:To assess the efficacy and safety of cerebroside carnosine for acute ischemic stroke.Method: Searches were performed in the MEDLINE,Cochrane library,CBM,CNKI,Wanfang and VMIS up to 2007.Randomized controlled trials(RCTs) or quasi-randomized controlled trials were collected.The quality of the studies was assessed and the meta-analysis was conducted according to the methods of Cochrane Collaboration's RevMan 4.2.Result:14 RCTs and 1 524 cases of acute ischemic stroke were included,only 2 were graded as high quality,and the others were graded as low quality.The meta-analysis of 10 trials involving the improvement of neurological deficit and 2 follow-up trials in 3 monthes indicated that the cerebroside carnosine could improve neurologic impairmenst significantly,[OR3.62,95%CI (2.52,5.19)]and[OR2.38,95%CI(1.28,4.40)]respectively.The meta-analysis of all the scores of NIHSS and ESS indicated that the cerebroside carnosine was more effective than those in the controlled group,[WMD-3.22,95%CI (-3.60,-2.84)]and[WMD17.64,95%CI(11.37,33.90)]respectively.The meta-analysis of the scores of ADL also indicated that the treatment group had an advantage,[WMD14.43,95%CI(0.16,28.69)].Conclusion:The cerebroside carnosine might improve the neurological deficit of patients with acute ischemic stroke,but seem unlikely to the long-term survival rate and disability rate.A high quality,large sample and long term randomized controlled follow-up trials are needed to evaluate the role of cerebroside carnosine for acute ischemic stroke.